Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Most claims about citrus/furanocoumarins/CYP3A4 are unsupported or not present in the provided label excerpts. While the label supports that atorvastatin is metabolized by CYP3A4 and that grapefruit juice can increase atorvastatin plasma concentrations, it does not provide support for citrus fruits broadly or furanocoumarins specifically. Several downstream risk statements are not supported as directly caused by citrus-related CYP3A4 inhibition in the provided label text, and the 24-hour avoidance timing is not supported.
Category Scores
Accurate Statements
CYP3A4 is involved in atorvastatin (Lipitor) metabolism.
“LIPITOR is metabolized by cytochrome P450 3A4…” (Section 7.1 Strong Inhibitors of CYP 3A4).
Grapefruit juice can increase plasma concentrations of atorvastatin by inhibiting CYP3A4.
“Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).” (Section 7.2 Grapefruit Juice).
Strong CYP3A4 inhibitors can increase plasma concentrations of atorvastatin.
“Concomitant administration… can lead to increases in plasma concentrations of atorvastatin.” (Section 7.1 Strong Inhibitors of CYP 3A4).
Increased atorvastatin plasma concentrations from CYP3A4 inhibition may increase risk of myopathy/rhabdomyolysis (as a class interaction risk).
“The risk of myopathy during treatment with statins is increased with concurrent administration… cyclosporine, or strong CYP 3A4 inhibitors…” (Section 7 overall). And: “The concomitant use of higher doses of atorvastatin with… strong CYP3A4 inhibitors… increases the risk of myopathy/rhabdomyolysis.” (Section 5.1 Skeletal Muscle).
Unsupported Statements
Citrus fruits such as oranges, grapefruits, and lemons contain furanocoumarins.
No mention of furanocoumarins or citrus fruit composition in the provided label excerpts.
Furanocoumarins in citrus fruits inhibit the enzyme CYP3A4.
No furanocoumarins or related mechanism described in the provided label excerpts.
Consuming citrus fruits while taking Lipitor can inhibit CYP3A4.
The provided label excerpt specifically addresses grapefruit juice (not citrus broadly) and does not describe citrus fruits overall inhibiting CYP3A4.
Increased levels of Lipitor in the bloodstream can lead to a higher risk of side effects such as muscle pain.
While the label supports myopathy/rhabdomyolysis risk with strong CYP3A4 inhibitors, it does not directly link “increased levels” from citrus to “muscle pain” in the provided excerpts.
Increased levels of Lipitor in the bloodstream can lead to a higher risk of side effects such as liver damage.
The provided label excerpts discuss liver dysfunction and monitoring, and CYP3A4 inhibition/plasma concentration increases, but they do not state that citrus-related increased levels cause liver damage.
Increased levels of Lipitor in the bloodstream can lead to a higher risk of side effects such as increased bleeding.
The provided label excerpts do not support “increased bleeding” as a consequence of increased atorvastatin plasma levels from citrus/CYP3A4 inhibition.
Lipitor is known to interact with citrus fruits.
The provided label excerpt supports grapefruit juice interaction specifically, not citrus fruits generally.
Patients should consult their healthcare provider before consuming citrus fruits while taking Lipitor.
No such counseling language is present in the provided label excerpts.
Contradictions
Low
AI Statement
A recommendation is to avoid consuming citrus fruits for at least 24 hours before taking Lipitor and for 24 hours after taking the medication.
Label Reference
Not found in provided label excerpts.
Important Omissions
If the intent is food interaction guidance, the label excerpt provided specifically mentions grapefruit juice and excessive consumption (>1.2 liters per day), but the AI claim does not accurately reflect that the label guidance is grapefruit-specific and dose/amount-related rather than a blanket 24-hour rule for all citrus.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because grapefruit juice interaction is supported in the label excerpts (increased atorvastatin plasma concentrations via CYP3A4 inhibition), the general direction of concern about interactions is plausible. However, the label does not support citrus fruits broadly (or furanocoumarins specifically) and does not support the stated 24-hour avoidance timing or the specific downstream adverse effect claims tied to citrus-related CYP3A4 inhibition. This creates risk of both misinformation and misapplication of guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Citrus/furanocoumarins mechanism and a blanket 24-hour citrus avoidance recommendation are not supported by the provided label excerpts; only grapefruit juice interaction via CYP3A4 is supported.
Suggested Improvement
Limit interaction statements to grapefruit juice as described in Section 7.2, avoid asserting furanocoumarins or non-grapefruit citrus mechanisms, remove the 24-hour before/after timing, and state adverse effects only as supported (e.g., myopathy/rhabdomyolysis risk with strong CYP3A4 inhibitors) without claiming liver damage or increased bleeding as consequences of citrus-induced CYP3A4 inhibition.